Renalytix PLC Renalytix to Participate in the BTIG Conference
February 09 2024 - 9:00AM
RNS Non-Regulatory
RNS Number : 6963C
Renalytix PLC
09 February 2024
Renalytix
plc
("Renalytix" or the "Company")
Renalytix to Participate in the BTIG MedTech,
Digital Health, Life Science & Diagnostic
Tools Conference
LONDON and SALT LAKE
CITY, February 9, 2024 -- Renalytix plc (NASDAQ: RNLX) (LSE:
RENX) announces that the Company will be participating in the
upcoming BTIG MedTech, Digital Health, Life Science &
Diagnostic Tools Conference, which will take place February 13-14,
2024 in Snowbird, Utah. Given the format of this event, no formal
company presentation is expected. Management will be participating
in one-on-one meetings with investors during the event and meetings
can be requested through BTIG.
For
further information, please contact:
Renalytix
plc
|
www.renalytix.com
|
James McCullough, CEO
|
Via Walbrook PR
|
|
|
Stifel (Nominated
Adviser, Joint Broker)
|
Tel: 020 7710 7600
|
Alex Price / Nicholas Moore / Nick Harland / Samira
Essebiyea
|
|
|
|
Investec Bank plc
(Joint Broker)
|
Tel: 020 7597 4000
|
Gary Clarence / Shalin Bhamra
|
|
|
|
Walbrook PR
Limited
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 / 07407
804 654
|
|
|
CapComm
Partners
|
|
Peter DeNardo
|
Tel: 415-389-6400 or investors@renalytix.com
|
|
| |
About
Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro
diagnostics and laboratory services company that is the global
founder and leader in the new field of bioprognosisâ„¢ for kidney
health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com.
This information is provided by Reach, the non-regulatory
press release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NRATLMJTMTIMBII
Renalytix (LSE:RENX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From Oct 2023 to Oct 2024